NCT00760084View on ClinicalTrials.gov

Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

September 30, 2005

Study Completion Date

February 29, 2008

Conditions
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Decitabine

Decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; ≥ 30% blasts).

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00760084 - Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter